{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:07:02Z","timestamp":1788570422903,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Health Research, Government of India"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40261-022-01238-3","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T20:02:11Z","timestamp":1673294531000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies"],"prefix":"10.1007","volume":"43","author":[{"given":"S Sajith","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-767X","authenticated-orcid":false,"given":"Bhavani Shankara","family":"Bagepally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Sasidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"1","key":"1238_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1238_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863\u201377.","journal-title":"Rheumatol Int"},{"key":"1238_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7015-7-12","volume":"7","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7:12.","journal-title":"BMC Med"},{"issue":"6","key":"1238_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679\u2013707.","journal-title":"Clin Ther"},{"issue":"6","key":"1238_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1238_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"1238_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331.","journal-title":"J Inflamm Res"},{"issue":"47","key":"1238_CR8","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359\u201368.","journal-title":"Oncogene"},{"key":"1238_CR9","unstructured":"United States Food and Drug Administration. Rituxan (rituximab) Label. United States: US FDA; 2006."},{"issue":"6","key":"1238_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, D\u00f6rner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1238_CR11","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","volume":"2","author":"L Garcia-Montoya","year":"2020","unstructured":"Garcia-Montoya L, Villota-Eraso C, Yusof MYM, Vital EM, Emery P. Lessons for rituximab therapy in patients with rheumatoid arthritis. Lancet Rheumatol. 2020;2(8):e497\u2013509.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"1238_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.semarthrit.2020.08.002","volume":"50","author":"DS Dalal","year":"2020","unstructured":"Dalal DS, Zhang T, Shireman TI. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020;50(5):822\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1238_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00296-016-3484-5","volume":"36","author":"S Ahmadiani","year":"2016","unstructured":"Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A. rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatol Int. 2016;36(9):1291\u2013300.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1238_CR14","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s12325-021-01733-7","volume":"38","author":"C Tan","year":"2021","unstructured":"Tan C, Li S, Yi L, Zeng X, Peng L, Qin S, et al. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in China: a cost-effectiveness analysis based on a mapping algorithm derived from a chinese population. Adv Ther. 2021;38(5):2571\u201385.","journal-title":"Adv Ther"},{"issue":"10","key":"1238_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047373","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS ONE. 2012;7(10): e47373.","journal-title":"PLoS ONE"},{"issue":"1","key":"1238_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3111\/13696990903508021","volume":"13","author":"Y Yuan","year":"2010","unstructured":"Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ. 2010;13(1):33\u201341.","journal-title":"J Med Econ"},{"issue":"1","key":"1238_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"Moher D, Shamseer L, PRISMA-P Group","year":"2015","unstructured":"Moher D, Shamseer L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"1238_CR18","unstructured":"Bagepally, BS, Haridoss, M. Cost-Effectiveness of TNF-alpha inhibitors, B-cell inhibitors and JAK inhibitors for the Treatment of Rheumatoid Arthritis: Systematic review and Meta-analysis. 2021 [cited 2022 June]. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021222541."},{"key":"1238_CR19","unstructured":"Registry, C. Center for the Evaluation of Value and Risk in Health [cited 2022 May]. Available from: https:\/\/cevr.tuftsmedicalcenter.org\/databases\/cea-registry."},{"issue":"1","key":"1238_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev."},{"key":"1238_CR21","unstructured":"Rohatgi, A. WebPlotDigitizer USA2021 [cited 2022 June]. Available from: https:\/\/automeris.io\/WebPlotDigitizer."},{"issue":"12","key":"1238_CR22","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jval.2019.09.2750","volume":"22","author":"BS Bagepally","year":"2019","unstructured":"Bagepally BS, Gurav YK, Anothaisintawee T, Youngkong S, Chaikledkaew U, Thakkinstian A. Cost Utility of sodium-glucose cotransporter 2 inhibitors in the treatment of metformin monotherapy failed type 2 diabetes patients: a systematic review and meta-analysis. Value Health. 2019;22(12):1458\u201369.","journal-title":"Value Health."},{"issue":"8","key":"1238_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Why it\u2019s time to abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u20134.","journal-title":"Pharmacoeconomics"},{"key":"1238_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jval.2015.09.2644","volume":"18","author":"JF O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony JF. The limitations of icers in screening interventions and the relative net benefit alternative. Value Health. 2015;18:7.","journal-title":"Value Health."},{"issue":"1","key":"1238_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12913-022-07595-1","volume":"22","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22(1):202.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1238_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000779","volume":"9","author":"BS Bagepally","year":"2022","unstructured":"Bagepally BS, Sajith Kumar S, Natarajan M, Sasidharan A. Incremental net benefit of cholecystectomy compared with alternative treatments in people with gallstones or cholecystitis: a systematic review and meta-analysis of cost\u2013utility studies. BMJ Open Gastroenterol. 2022;9(1): e000779.","journal-title":"BMJ Open Gastroenterol"},{"key":"1238_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fphar.2022.1090361","volume":"13","author":"SS Kumar","year":"2022","unstructured":"Kumar SS, Haridoss M, Venkataraman K, Bagepally BS. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: a systematic review and meta-analysis of cost-utility studies. Front Pharmacol. 2022;13:2.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1238_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264563","volume":"17","author":"A Sasidharan","year":"2022","unstructured":"Sasidharan A, Bagepally BS, Kumar SS, Jagadeesh KV, Natarajan M. Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: a systematic review and meta-analysis of cost-utility studies. PLoS ONE. 2022;17(6): e0264563.","journal-title":"PLoS ONE"},{"key":"1238_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00228-021-03242-6","volume":"78","author":"B Bagepally","year":"2022","unstructured":"Bagepally B, Sasidharan A. Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies. Eur J Clin Pharmacol. 2022;78:2.","journal-title":"Eur J Clin Pharmacol"},{"key":"1238_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11695-021-05415-9","volume":"31","author":"P Noparatayaporn","year":"2021","unstructured":"Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, Bagepally B, Thakkinstian A. Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences. Obes Surg. 2021;31:1\u201312.","journal-title":"Obes Surg"},{"key":"1238_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001020","volume":"8","author":"B Bagepally","year":"2020","unstructured":"Bagepally B, Chaikledkaew U, Gurav Y, Anothaisintawee T, Youngkong S, Chaiyakunapruk N, et al. Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Res Care. 2020;8: e001020.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1238_CR32","unstructured":"Bank, TW. World Bank Country and Lending Groups \u2013 World Bank Data Help Desk 2021 [cited 2022 June]. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"1238_CR33","unstructured":"Corporation., M. Microsoft Excel [Internet]. 2018 [cited 2022 July]. Available from: https:\/\/office.microsoft.com\/excel."},{"key":"1238_CR34","unstructured":"StataCorp. Stata Statistical Software: Release 16: College Station, TX: StataCorp LLC.; 2019 [cited 2022. 17:[Available from: https:\/\/www.stata.com\/."},{"issue":"4","key":"1238_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Exp Rev Pharmacoecon Outcomes Research. 2016;16(4):513\u201323.","journal-title":"Exp Rev Pharmacoecon Outcomes Research."},{"issue":"4","key":"1238_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1 Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol."},{"key":"1238_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","volume":"87","author":"M Hultcrantz","year":"2017","unstructured":"Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE working group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4\u201313.","journal-title":"J Clin Epidemiol"},{"issue":"Suppl 2","key":"1238_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3310\/hta13suppl2-04","volume":"13","author":"A Bagust","year":"2009","unstructured":"Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, et al. rituximab for the treatment of rheumatoid arthritis. Health Technol Assess. 2009;13(Suppl 2):23\u20139.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1238_CR39","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00296-010-1502-6","volume":"31","author":"M Benucci","year":"2011","unstructured":"Benucci M, Saviola G, Baiardi P, Manfredi M. Cost-effectiveness treatment with rituximab in patients with rheumatoid arthritis in real life. Rheumatol Int. 2011;31(11):1465\u20139.","journal-title":"Rheumatol Int"},{"key":"1238_CR40","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fphar.2018.00794","volume":"9","author":"VV Boyadzieva","year":"2018","unstructured":"Boyadzieva VV, Stoilov N, Stoilov RM, Tachkov K, Kamusheva M, Mitov K, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794.","journal-title":"Front Pharmacol"},{"issue":"34","key":"1238_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22340","volume":"22","author":"S Brown","year":"2018","unstructured":"Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, et al. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technol Assess. 2018;22(34):1\u2013280.","journal-title":"Health Technol Assess"},{"issue":"11","key":"1238_CR42","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1080\/03007995.2018.1497957","volume":"34","author":"L Claxton","year":"2018","unstructured":"Claxton L, Taylor M, Gerber RA, Gruben D, Moynagh D, Singh A, et al. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Curr Med Res Opin. 2018;34(11):1991\u20132000.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1238_CR43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3111\/13696998.2012.665110","volume":"15","author":"A Diamantopoulos","year":"2012","unstructured":"Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576\u201385.","journal-title":"J Med Econ"},{"issue":"4","key":"1238_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/kep425","volume":"49","author":"TA Hallinen","year":"2010","unstructured":"Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford). 2010;49(4):767\u201377.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1238_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220142","volume":"14","author":"S Huoponen","year":"2019","unstructured":"Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, et al. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis. PLoS ONE. 2019;14(7): e0220142.","journal-title":"PLoS ONE"},{"issue":"7","key":"1238_CR46","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/13696998.2017.1307205","volume":"20","author":"JP Jansen","year":"2017","unstructured":"Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017;20(7):703\u201314.","journal-title":"J Med Econ"},{"issue":"1","key":"1238_CR47","first-page":"73","volume":"27","author":"AR Karpes Matusevich","year":"2021","unstructured":"Karpes Matusevich AR, Lai LS, Chan W, Swint JM, Cantor SB, Suarez-Almazor ME, et al. Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2021;27(1):73\u201383.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"1238_CR48","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1185\/03007990802321683","volume":"24","author":"A Kielhorn","year":"2008","unstructured":"Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008;24(9):2639\u201350.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1238_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40744-021-00300-4","volume":"8","author":"S Li","year":"2021","unstructured":"Li S, Li J, Peng L, Li Y, Wan X. Cost-effectiveness of triple therapy vs. biologic treatment sequence as first-line therapy for rheumatoid arthritis patients after methotrexate failure. Rheumatol Ther. 2021;8(2):775\u201391.","journal-title":"Rheumatol Ther."},{"issue":"1","key":"1238_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/03007995.2020.1846172","volume":"37","author":"E Lopatina","year":"2021","unstructured":"Lopatina E, Marshall DA, Coupal L, Le Lorier J, Choquette D. Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis. Curr Med Res Opin. 2021;37(1):157\u201366.","journal-title":"Curr Med Res Opin"},{"key":"1238_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","volume":"17","author":"SH Manders","year":"2015","unstructured":"Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015;17:134.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1238_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10198-009-0205-y","volume":"11","author":"S Merkesdal","year":"2010","unstructured":"Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. Eur J Health Econ. 2010;11(1):95\u2013104.","journal-title":"Eur J Health Econ"},{"issue":"10","key":"1238_CR53","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s10067-020-05087-3","volume":"39","author":"F Navarro","year":"2020","unstructured":"Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, et al. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol. 2020;39(10):2919\u201330.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1238_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10067-021-05876-4","volume":"41","author":"C Tan","year":"2022","unstructured":"Tan C, Luo X, Li S, Yi L, Zeng X, Peng L, et al. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis. Clin Rheumatol. 2022;41(1):63\u201373.","journal-title":"Clin Rheumatol"},{"issue":"14","key":"1238_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1\u2013278.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1238_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S0266462309090230","volume":"25","author":"P Lindgren","year":"2009","unstructured":"Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care. 2009;25(2):181\u20139.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"1238_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/BOR.0b013e3283369cb8","volume":"22","author":"B Marston","year":"2010","unstructured":"Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):307\u201315.","journal-title":"Curr Opin Rheumatol"},{"key":"1238_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, et al. B cells in RHEUMATOID arthritis: pathogenic mechanisms and treatment prospects. Front Immunol. 2021;12: 750753.","journal-title":"Front Immunol"},{"issue":"3","key":"1238_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discovery. 2021;20(3):179\u201399.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"1238_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Research. 2018;6(1):15.","journal-title":"Bone Research."},{"key":"1238_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788830","volume":"12","author":"C Kaegi","year":"2021","unstructured":"Kaegi C, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of second- and third-generation CD20-targeting biologics in treating immune-mediated disorders. Front Immunol. 2021;12: 788830.","journal-title":"Front Immunol"},{"issue":"3","key":"1238_CR62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/14740338.2017.1273899","volume":"16","author":"J Braun","year":"2017","unstructured":"Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017;16(3):289\u2013302.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"1238_CR63","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/1744666X.2017.1259068","volume":"13","author":"P Mota","year":"2017","unstructured":"Mota P, Reddy V, Isenberg D. Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expert Rev Clin Immunol. 2017;13(7):667\u201376.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1238_CR64","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3899\/jrheum.120886","volume":"40","author":"W Stohl","year":"2013","unstructured":"Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol. 2013;40(5):579.","journal-title":"J Rheumatol"},{"issue":"2","key":"1238_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3899\/jrheum.120441","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, et al. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013;40(2):137\u201343.","journal-title":"J Rheumatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01238-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01238-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01238-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T11:11:12Z","timestamp":1675941072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01238-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01238-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"18 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was received for this work. However, the Department of Health Research Government of India funds the Health Technology Assessment resource centre, ICMR-NIE. Funders had no role in the conceptualisation, conduction, and manuscript preparation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SK: data curation, original draft, review & editing. BSB: conceptualisation, data curation, formal analysis, review & editing. AS: Original draft, review & editing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contribution"}},{"value":"The authors (SK, AK, BSB) have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required. Study synthesizes the available evidence and does not involve any patients\/participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable, no patients involved.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The manuscript has been read and approved by all named authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data sources used are properly disclosed and no additional data available. All the data supporting the findings of this study are available within the article and its supplementary materials.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}